Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model. 2014

Jun Wu, and Shunmei Huang, and Xiaoli Zhao, and Mingfa Chen, and Yong Lin, and Youchen Xia, and Chan Sun, and Xuecheng Yang, and Junzhong Wang, and Yan Guo, and Jingjiao Song, and Ejuan Zhang, and Baoju Wang, and Xin Zheng, and Joerg F Schlaak, and Mengji Lu, and Dongliang Yang
Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

We have previously shown that poly(I:C) activates murine hepatic cells to produce interferon (IFN) and suppresses hepatitis B virus (HBV) replication in vitro. Therefore, we addressed whether poly(I:C) is able to induce the clearance of HBV in vivo. The chronic HBV replication mouse model was established by the hydrodynamic injection (HI) of pAAV-HBV1.2 into the tail veins of wild-type and IFN-α/βR-, IFN-γ-, and CXCR3-deficient C57BL/6 mice. Fourteen days post-HI of pAAV-HBV1.2, mice were administered poly(I:C) by intraperitoneal injection, intramuscular injection, or HI. Only treatment of poly(I:C) by HI led to HBV clearance in wild-type C57BL/6 mice. Serum HBsAg disappeared within 40 days postinfection (dpi) in mice that received poly(I:C) by HI, and this was accompanied by the appearance of anti-HBs antibodies. HBV-specific T-cell and antibody responses were significantly enhanced by HI of poly(I:C). HBV replication intermediates and HBcAg-positive hepatocytes were eliminated in the liver. HI of poly(I:C) induced the production of IFNs in mice and enhanced the levels of cytokines, IFN-stimulated genes, and T-cell markers in the liver. Importantly, poly(I:C)-induced HBV clearance was impaired in IFN-α/βR-, IFN-γ-, and CXCR3-deficient mice, indicating that the induction of type I IFN and the stimulation and recruitment of T cells into the liver are essential for HBV clearance in this model. Taken together, the application of poly(I:C) by HI into the liver enhances innate and adaptive immune responses and leads to HBV clearance in an HBV mouse model, implicating the potential of intrahepatic Toll-like receptor 3 (TLR3) activation for the treatment of chronic hepatitis B patients. OBJECTIVE It has become well accepted that immunomodulation is a potentially useful approach to treat chronic viral infection. Recently, combinations of antiviral treatment and therapeutic vaccinations were evaluated for therapies of chronic hepatitis B virus (HBV) infection. Activation of the innate immune branch may also be important for viral control and contributes to HBV clearance. Our present study demonstrated that hepatic TLR3 activation led to clearance of hepatitis B virus in an HBV mouse model. For the first time, we showed that HBV clearance in this model is dependent not only on type I interferon (IFN) but also on type II IFN, indicating a coordinated action of innate and adaptive immune responses. T-cell recruitment appeared to be critical for the success of TLR3-mediated antiviral action. These findings implicate the potential of intrahepatic TLR3 activation for the treatment of chronic HBV infection.

UI MeSH Term Description Entries
D007372 Interferons Proteins secreted by vertebrate cells in response to a wide variety of inducers. They confer resistance against many different viruses, inhibit proliferation of normal and malignant cells, impede multiplication of intracellular parasites, enhance macrophage and granulocyte phagocytosis, augment natural killer cell activity, and show several other immunomodulatory functions. Interferon
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005260 Female Females
D006515 Hepatitis B virus The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum. Dane Particle,Hepatitis Virus, Homologous Serum,B virus, Hepatitis,Hepatitis B viruses,Particle, Dane,viruses, Hepatitis B
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications

Related Publications

Jun Wu, and Shunmei Huang, and Xiaoli Zhao, and Mingfa Chen, and Yong Lin, and Youchen Xia, and Chan Sun, and Xuecheng Yang, and Junzhong Wang, and Yan Guo, and Jingjiao Song, and Ejuan Zhang, and Baoju Wang, and Xin Zheng, and Joerg F Schlaak, and Mengji Lu, and Dongliang Yang
January 2014, PloS one,
Jun Wu, and Shunmei Huang, and Xiaoli Zhao, and Mingfa Chen, and Yong Lin, and Youchen Xia, and Chan Sun, and Xuecheng Yang, and Junzhong Wang, and Yan Guo, and Jingjiao Song, and Ejuan Zhang, and Baoju Wang, and Xin Zheng, and Joerg F Schlaak, and Mengji Lu, and Dongliang Yang
January 2015, PloS one,
Jun Wu, and Shunmei Huang, and Xiaoli Zhao, and Mingfa Chen, and Yong Lin, and Youchen Xia, and Chan Sun, and Xuecheng Yang, and Junzhong Wang, and Yan Guo, and Jingjiao Song, and Ejuan Zhang, and Baoju Wang, and Xin Zheng, and Joerg F Schlaak, and Mengji Lu, and Dongliang Yang
October 2002, Proceedings of the National Academy of Sciences of the United States of America,
Jun Wu, and Shunmei Huang, and Xiaoli Zhao, and Mingfa Chen, and Yong Lin, and Youchen Xia, and Chan Sun, and Xuecheng Yang, and Junzhong Wang, and Yan Guo, and Jingjiao Song, and Ejuan Zhang, and Baoju Wang, and Xin Zheng, and Joerg F Schlaak, and Mengji Lu, and Dongliang Yang
January 2015, Journal of innate immunity,
Jun Wu, and Shunmei Huang, and Xiaoli Zhao, and Mingfa Chen, and Yong Lin, and Youchen Xia, and Chan Sun, and Xuecheng Yang, and Junzhong Wang, and Yan Guo, and Jingjiao Song, and Ejuan Zhang, and Baoju Wang, and Xin Zheng, and Joerg F Schlaak, and Mengji Lu, and Dongliang Yang
July 2007, International journal of molecular medicine,
Jun Wu, and Shunmei Huang, and Xiaoli Zhao, and Mingfa Chen, and Yong Lin, and Youchen Xia, and Chan Sun, and Xuecheng Yang, and Junzhong Wang, and Yan Guo, and Jingjiao Song, and Ejuan Zhang, and Baoju Wang, and Xin Zheng, and Joerg F Schlaak, and Mengji Lu, and Dongliang Yang
January 2016, Methods in molecular biology (Clifton, N.J.),
Jun Wu, and Shunmei Huang, and Xiaoli Zhao, and Mingfa Chen, and Yong Lin, and Youchen Xia, and Chan Sun, and Xuecheng Yang, and Junzhong Wang, and Yan Guo, and Jingjiao Song, and Ejuan Zhang, and Baoju Wang, and Xin Zheng, and Joerg F Schlaak, and Mengji Lu, and Dongliang Yang
January 1981, Journal of interferon research,
Jun Wu, and Shunmei Huang, and Xiaoli Zhao, and Mingfa Chen, and Yong Lin, and Youchen Xia, and Chan Sun, and Xuecheng Yang, and Junzhong Wang, and Yan Guo, and Jingjiao Song, and Ejuan Zhang, and Baoju Wang, and Xin Zheng, and Joerg F Schlaak, and Mengji Lu, and Dongliang Yang
March 2015, World journal of gastroenterology,
Jun Wu, and Shunmei Huang, and Xiaoli Zhao, and Mingfa Chen, and Yong Lin, and Youchen Xia, and Chan Sun, and Xuecheng Yang, and Junzhong Wang, and Yan Guo, and Jingjiao Song, and Ejuan Zhang, and Baoju Wang, and Xin Zheng, and Joerg F Schlaak, and Mengji Lu, and Dongliang Yang
November 1995, The Journal of pediatrics,
Jun Wu, and Shunmei Huang, and Xiaoli Zhao, and Mingfa Chen, and Yong Lin, and Youchen Xia, and Chan Sun, and Xuecheng Yang, and Junzhong Wang, and Yan Guo, and Jingjiao Song, and Ejuan Zhang, and Baoju Wang, and Xin Zheng, and Joerg F Schlaak, and Mengji Lu, and Dongliang Yang
January 2013, PloS one,
Copied contents to your clipboard!